We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Eurand N.V. (MM) | NASDAQ:EURX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.985 | 0 | 00:00:00 |
Date: Tuesday, October 5, 2010 Time: 9:00 a.m. Local Time Place: The Waldorf Hilton London, England
A live audio webcast of the presentation can be accessed in the investor relations section of Eurand's web site at www.eurand.com and will be available via replay for 30 days.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking orally disintegrating tablet (ODT) formulations. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.
Contacts: Bill Newbould Vice President, Investor Relations Eurand N.V. +1 267-759-9335 Email Contact Nick Laudico/Sara Pellegrino The Ruth Group +1 646-536-7030/7002 Email Contact Email Contact
1 Year Eurand N.V. (MM) Chart |
1 Month Eurand N.V. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions